Company news
Apimeds Pharmaceuticals US, Inc. news in 2026
Apimeds Pharmaceuticals US, Inc.'s news releases, calls and decks from 2026, newest first.
IBN Announces CryptoCurrencyWire Audio Production Featuring Dr. Vin Menon, CEO of MindWave Innovations Inc.
November 3, 2026
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) in connection with its $13.5 Million Initial Public Offering
September 13, 2026
MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October
July 28, 2026
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
May 5, 2026
Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
May 4, 2026
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS: 006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
March 24, 2026
Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100
February 12, 2026
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
February 11, 2026